China's traditional Chinese medicine industry will present five development trends in the future

[introduction to articles on chinapharma.com] in recent years, the industry of traditional Chinese medicine has developed well Judging from the current enthusiasm for planting traditional Chinese medicine in China, the next two years will be a big year for the production of traditional Chinese medicine Although the overall market of domestic drug market still has room to continue to rise, huge risks of inventory and production expansion are brewing It is expected that before July 2017, the drug market may turn around (China's traditional Chinese medicine industry will present five development trends in the future picture source: Baidu picture) (I) the price of traditional Chinese medicine has entered the rising channel The comprehensive 200 index reflecting the overall operation of the domestic traditional Chinese medicine market has risen from 2215.36 at the beginning of 2016 to 2549.19 on December 7, 2016, an increase of 15% In addition to the comprehensive index, the price of some Chinese herbal medicines has increased significantly According to the data of tiandi.com, the annual growth rate of Evodia rutaecarpa (Jiangxi xiaohuatong specification, lotus pond market) is 372.73%; that of Panax notoginseng (Yunnan 120 Chunqi specifications, lotus pond market) is 170%; that of Atractylodes macrocephala (Anhui Tongtong specification, Yulin market) is 115.38% As of October 2016, the prices of angelica, dangshen and Schisandra have increased by 37.7%, 99.5% and 103.6% respectively In fact, in addition to the above medicinal materials, most of the Chinese medicinal materials showed an upward trend in 2016, including small varieties of medicinal materials According to the report on in-depth research and investment forecast of Chinese traditional medicine industry in 2017-2021 released by CIC consultants, the next two years will be a big year for the output of Chinese traditional medicine in terms of the current enthusiasm for planting a piece of Chinese traditional medicine in China Although the overall market of domestic drug market still has room to continue to rise, huge risks of inventory and production expansion are brewing It is expected that before July 2017, the drug market may turn around (II) more medicinal materials will be included in the European Pharmacopoeia As of May 2016, 66 kinds of Chinese medicinal materials have been included in the European Pharmacopoeia The future goal is to include at least 300 kinds of Chinese medicinal materials commonly used in traditional Chinese medicine into the European Pharmacopoeia At present, there are 66 kinds of Chinese herbal medicines in the European Pharmacopoeia, including ginseng, tangerine peel, Atractylodes macrocephala, rhubarb, hydrangea, Polygonum cuspidatum and Panax notoginseng, accounting for more than one third of the 184 kinds of herbal medicines in the European Pharmacopoeia In addition to the European Pharmacopoeia, some Chinese medicine standards have been listed in the USP, and some drugs are under review by the USP Committee For example, Schisandra chinensis, coix seed, cassia twig, red ginseng, honeysuckle, Polygonum multiflorum, Salvia miltiorrhiza, Panax notoginseng, Ganoderma lucidum and other traditional Chinese medicine standards have been included in the herbal volume of the United States Pharmacopoeia, among which, Salvia miltiorrhiza, Panax notoginseng and Ganoderma lucidum are included in the food supplement volume at the same time In the future, the varieties of traditional Chinese medicine included in the collection will have the standards and specifications recognized by Europe and the United States in terms of safety, quality, efficacy, etc., which will lay the foundation for the wider acceptance and use of traditional Chinese medicine abroad, and also be the step to open the export channel of traditional Chinese medicine (3) strict inspection of the quality of Chinese herbal pieces on May 24, 2016, the State Administration of traditional Chinese Medicine issued the notice of "special inspection plan for the management of Chinese Herbal Pieces in national medical institutions" to strictly inspect the quality of Chinese herbal pieces At the same time, in the drug quality reports released by various provinces, pieces of Chinese herbal medicine are often found in unqualified drugs The production enterprise of Chinese herbal pieces has become the key object of flight inspection On the one hand, since 2016, many provinces have released the key regulatory catalogue of Chinese herbal pieces, which shows that the quality inspection and tracking of Chinese herbal medicines have become a normal In the future, the treatment of traditional Chinese medicine will be more fierce, which will promote the development of Chinese herbal medicine industry towards more quality On the other hand, the national level attaches great importance to and promotes the development of traditional Chinese medicine to bring benefits to the market of decoction pieces According to the 2017-2021 report on in-depth research and investment prospects of Chinese traditional medicine industry released by CIC consultants, enterprises that adhere to quality operation and have systematic marketing network will become the winner of the market (IV) intensified competition of formula granules CFDA issued the measures for the administration of traditional Chinese medicine formula granules (Draft for comments) as of March 1, 2016
Since the release of the measures for the administration of traditional Chinese medicine formula granules (Draft for comments), the outline of strategic planning for the development of traditional Chinese medicine (2016-2030) has incorporated traditional Chinese medicine formula granules into the 13th five year plan; the technical requirements for the quality control and standard setting of traditional Chinese Medicine formula granules (Draft for comments) issued by the national pharmacopoeia committee has also ended the collection of feedback opinions in early November, releasing that the industry will A positive signal from pilot to formal production and gradual market opening In the future, the weak competition and relative monopoly of pilot enterprises are expected to be broken, and the competition of formula particles may be intensified (V) due to the depression of traditional Chinese medicine injection and supervision of raw materials of traditional Chinese medicine, the growth rate of traditional Chinese medicine will slow down in 2016, which is expected to be 4.9% According to the data reports of 66 listed Chinese patent medicine enterprises, the overall growth rate of 10% is flat, and there are as many as 18 enterprises with negative growth in net profit, including 5 enterprises with negative growth in both revenue and net profit The overall situation of the industry is not optimistic, but with the introduction of a series of new policies, the Chinese patent medicine industry ushered in a period of policy dividend to promote development During the 13th five year plan, the scale of traditional Chinese medicine industry will be doubled By 2020, the main business income of large-scale traditional Chinese medicine industrial enterprises will be 1582.3 billion yuan National policies support the secondary development of traditional Chinese medicine: at present, there are more than 270 large varieties of traditional Chinese medicine, accounting for 50% of the total sales of traditional Chinese medicine market The 12th Five Year Plan for science and technology of the people's Republic of China clearly proposes that the next five years should focus on supporting and developing the secondary development of 30 traditional Chinese medicine varieties There are now 24 new traditional Chinese medicines listed in the 13th five year plan to develop major innovative drugs In the next five years, traditional Chinese medicine industry will step into the period of innovation and development brought by favorable policies.